Alpha-Synuclein in Neurodegeneration: From Pathophysiologic Mechanisms to Therapeutic Strategies
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".
Deadline for manuscript submissions: 31 March 2026 | Viewed by 33
Special Issue Editor
Interests: Parkinson’s disease; alpha-synuclein; dopaminergic neuron; apoptosis; neuroinflamation; acupuncture; neuroprotection
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to announce a Special Issue dedicated to exploring the pivotal role of alpha-synuclein in neurodegenerative diseases. As a central player in the pathology of Parkinson’s disease and related synucleinopathies, alpha-synuclein has emerged as both a critical biomarker and a promising therapeutic target.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- Mechanisms of alpha-synuclein aggregation, misfolding, and propagation;
- Cellular and molecular pathways linking alpha-synuclein to neurodegeneration;
- Advances in diagnostic biomarkers and imaging of alpha-synuclein pathology;
- Preclinical and clinical therapeutic strategies targeting alpha-synuclein (immunotherapy, small molecules, gene therapy, etc.);
- Translational studies bridging basic mechanisms with therapeutic applications.
This Special Issue aims to provide a comprehensive overview of current advances while fostering new directions in pathophysiology, diagnosis, and treatment strategies for alpha-synuclein–related neurodegenerative diseases.
I look forward to receiving your contributions.
Dr. Sujung Yeo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- alpha-synuclein
- neurodegeneration
- Parkinson's disease
- pathophysiology
- mechanism
- therapy
- synucleinopathy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
